menu
    • menu
    [{"orgOrder":0,"company":"Parion Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Idrevloride","moa":"Amiloride-sensitive sodium channel, ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parion Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"P-1037","moa":"Amiloride-sensitive sodium channel, ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parion Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Hypertonic Saline","moa":"Electrolyte\/osmotic gradient","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parion Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"P-552","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Parion Sciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Parion Sciences

    Menu

    Parion Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hypertonic Saline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

                            Details : Hypertonic Saline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ciliary Motility Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 18, 2016

                            Lead Product(s) : Hypertonic Saline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

                            Details : P-321 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 13, 2016

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Ey...

                            Details : P-321 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 07, 2016

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idrevloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for ...

                            Details : Idrevloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2016

                            Lead Product(s) : Idrevloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-1037

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

                            Details : P-1037 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2015

                            Lead Product(s) : P-1037

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

                            Details : P-321 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 16, 2014

                            Lead Product(s) : P-321

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Parion Sciences

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-552

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

                            Details : P-552 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 09, 2011

                            Lead Product(s) : P-552

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth